Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Revolution Medicines, Inc. RVMD

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
146.00
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 3 7 5 3 — 9 2 1 9 — 3 3
Insider Ownership
8.48%

Capital & Financial Ratios

Market Cap
42,140.00
Revenue
26.91
Net Income
(1,768.28)
Free Cash Flow
(1,232.13)
Net Debt
(2,901.99)
Current Ratio
11.38
Debt/Equity
0.40
P/E ratio
0.00
P/S ratio
1,496.48
P/B ratio
15.45
Past 5Y EPS Growth
(27.80%)
This Y EPS Growth
(63.29%)
Next Y EPS Growth
38.39%
Next 5Y EPS Growth
23.90%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 1,852.96 2,289.30 2,025.68 3,937.97
Receivables 1.25 — — —
Inventory — — — —
Other — — — —
1,879.28 2,327.63 2,075.04 4,028.34
2023 2024 2025 Q'26
Payables 61.79 54.43 64.62 88.42
ST’ Debt — — — —
Other — — — —
143.85 163.91 290.42 354.06
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’23 7.01 3.82 — 0.74
11.58
’22 7.58 9.12 3.36 15.33
35.38
’21 10.13 8.70 1.10 9.46
29.39
’20 11.55 10.03 12.66 8.75
42.98
’19 13.17 12.28 12.51 12.09
50.04
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (354.16) (387.32) — —
—
’25 (194.43) (221.76) (207.31) (274.24)
(897.74)
’24 (160.56) (128.17) (130.42) (138.29)
(557.44)
’23 (62.39) (67.12) (100.50) (120.56)
(350.57)
’22 (55.16) (55.72) (51.74) (61.79)
(224.40)
’21 (37.25) (34.08) (36.59) (39.26)
(147.18)
’20 (28.02) (19.99) (27.02) (25.03)
(100.06)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (355.70) (389.60) — —
—
’25 (197.70) (229.21) (210.66) (276.16)
(913.73)
’24 (163.73) (130.57) (133.94) (139.51)
(567.74)
’23 (64.15) (68.24) (103.03) (122.88)
(358.30)
’22 (57.05) (58.24) (55.26) (64.66)
(235.22)
’21 (40.82) (35.39) (37.04) (40.45)
(153.71)
’20 (28.62) (20.46) (27.71) (26.20)
(103.00)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (2.29) (3.06) — —
—
’25 (1.13) (1.31) (1.61) (1.86)
(5.95)
’24 (0.70) (0.81) (0.94) (1.12)
(3.58)
’23 (0.72) (0.92) (0.99) (1.14)
(3.86)
’22 (0.78) (0.82) (0.87) (0.63)
(3.08)
’21 (0.53) (0.60) (0.72) (0.71)
(2.57)
’20 (0.74) (0.46) (0.42) (0.52)
(2.01)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 14.08 15.44 25.93 29.17 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 27.49 35.60 62.40 81.97 — — —
High Price
— — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 246 378 534 883 — — —
Employees
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.14 0.03 0.00 0.00 — — —
Revenue/Emp
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 35.38 11.58 — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% — — — — —
Gross Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (249.12) (439.89) (600.85) (1,131.30) ‡‡‡‡‡ — —
EBT
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (704.14%) (3,798.71%) 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (248.70) (436.37) (600.09) (1,131.30) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.58 (12.90) (32.74) (11.27) — — —
Depreciation
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.44 0.10 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.08) (3.86) (3.58) (5.95) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.78) (3.10) (3.32) (4.72) ‡‡‡‡ — —
Cash Flow/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.13) (0.07) (0.06) (0.08) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.92) (3.17) (3.38) (4.81) — — —
Free CF/Sh
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.50 16.14 13.50 8.58 ‡‡‡‡‡ — —
Book Value/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 80.63 113.15 167.74 190.13 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.30 118.70 — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.70 1.75 — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 35.88 52.18 — — ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.40) (3.92) — — — — —
EV/FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (224.40) (350.57) (557.44) (897.74) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (10.82) (7.73) (10.31) (15.99) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (235.22) (358.30) (567.74) (913.73) ‡‡‡‡‡ — —
FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 598.20 1,735.43 2,163.72 1,784.61 — — —
Working Cap'
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64.21 — — 268.45 — — —
Total Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (580.74) (1,852.95) (2,289.30) (1,757.23) — — —
Net Debt
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 685.19 1,826.19 2,265.20 1,631.30 — — —
Sh' Equity
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.09%) (30.37%) (25.98%) (46.06%) ‡‡‡‡‡ — —
ROA
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (154.55%) 0.00% 0.00% 0.00% — — —
ROIC
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (38.63%) (34.75%) (29.33%) (58.07%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Revolution Medicines (RVMD), a clinical-stage biotech targeting RAS-driven cancers with promising candidates like RMC-6236, has seen its stock surge over 100% from 2024 lows on positive Phase 1b data and oncology M&A fervor. However, beneath the hype lies a high-risk profile: revenue has cratered 67% to $11.6 million in 2023 amid ballooning headcount (up 494% to 534 employees), slashing per-employee revenue by 94%, while losses exploded to -$600 million in 2024 with relentless cash burn exceeding $550 million annually. A robust balance sheet—$2.3 billion in equity and net cash—provides a 4-year runway, but dilution history, insider selling totaling $35 million (no buys), and negative ROE/ROA signal caution.

Analysts forecast a dramatic revenue inflection, dipping to $3.9 million in 2025 before surging 816% to $35.6 million in 2026 and over 8x more in 2027, driven by potential Phase 3 success and FDA fast-tracking. Yet, EPS forecasts worsen to -6.53 by 2026, valuations remain frothy (PS at 119x, EV/Sales 52x), and risks loom large: 60% oncology trial attrition, competitor disappointments like Lumakras, and macro pressures from higher rates. For risk-averse investors, RVMD is a speculative hold—monitor Phase 3 data for binary upside amid weak fundamentals-price correlation.

Read full commentary →

Revolution Medicines, Inc. (RVMD) Latest News

News by impact score

Fine-tune

17 Sep

4 www.fool.com, 4:20 AM
Revolution Medicines hit a major milestone, prompting assessment of whether RVMD stock represents a buy. Major milestone signals significant strategic progress likely to alter company trajectory and investor sentiment.

16 Sep

4 , 10:33 AM
Revolution Medicines (RVMD) reports promising clinical results that signal a potential paradigm shift in treatment. Promising clinical results are likely to significantly alter Revolution Medicines' trajectory and investor sentiment.

14 Sep

4 , 4:05 PM
Revolution Medicines receives U.S. FDA Breakthrough Therapy Designation for daraxonrasib combined with chemotherapy in first-line metastatic pancreatic cancer. Breakthrough Therapy Designation for core RAS inhibitor asset in pancreatic cancer accelerates regulatory path and elevates commercial prospects.

11 Sep

4 , 8:40 PM
Revolution Medicines receives its first drug approval but the market shows no meaningful reaction. First drug approval constitutes a major milestone that can substantially alter the company's trajectory and investor sentiment.

10 Sep

4 , 2:40 PM
Revolution Medicines secured approval for its 'miracle' cancer drug but faces Wall Street pressure for additional progress. Cancer drug approval marks major regulatory win likely to shift RVMD trajectory and investor views.

4 , 1:14 PM
Revolution Medicines advances a miracle cancer drug that positions the company for expanded market share gains in oncology treatments. A breakthrough cancer drug directly strengthens Revolution Medicines' competitive positioning and growth outlook.

4 , 11:29 AM
Morgan Stanley states Revolution Medicines gains from drug portfolio expansion and new combination therapies. Analyst note on RVMD pipeline expansions and therapies points to major strategic advances altering company trajectory.

5 Sep

4 , 1:06 AM
Revolution Medicines (RVMD) gains FDA approval. Cancer study appears in leading journal. FDA approval marks major regulatory success for core oncology pipeline.

3 , 10:13 AM
RVMD stock appears overvalued despite recent drug approval. Drug approval at RVMD supports product progress yet valuation concerns limit fundamental trajectory shifts.

4 Sep

4 , 1:22 PM
Revolution Medicines priced Rasonque at $39,800 per 30-day supply, raising questions on whether patient access will match the drug's clinical breakthrough. Drug pricing at this level directly affects RVMD revenue potential, adoption rates, and investor views on commercial success.

4 www.marketbeat.com, 1:15 PM
Revolution Medicines secured breakthrough status for a key oncology candidate, triggering questions around next steps for commercialization, partnerships and pipeline expansion amid heightened investor focus on its RAS-focused platform. Breakthrough designation materially speeds regulatory timelines and elevates RVMD's competitive stance in targeted cancer therapies.

3 Sep

4 , 10:31 AM
42% of US cancer patients deplete savings in two years due to treatment costs. Bernie Sanders proposes a $400,000 solution targeting high drug prices at companies including Revolution Medicines. Potential price pressure from political focus on cancer drug costs could constrain Revolution Medicines revenue and market access.

2 Sep

4 , 5:50 PM
New England Journal of Medicine published Phase 1/2 clinical data on Revolution Medicines’ daraxonrasib (RASONQUE) in metastatic non-small cell lung cancer. NEJM publication of daraxonrasib Phase 1/2 data boosts pipeline credibility and can drive significant investor interest and valuation gains.

29 Aug

5 www.thestreet.com, 1:07 PM
Revolution Medicines' new therapy proves effective against pancreatic cancer, offering viable treatment for patients facing the deadliest form of the disease and advancing the company's clinical pipeline. Breakthrough efficacy data in pancreatic cancer directly elevates RVMD's competitive standing and long-term growth prospects in oncology.

28 Aug

5 www.marketbeat.com, 3:02 PM
Revolution Medicines, Inc. (RVMD) secures FDA approval for RASONQUE in metastatic pancreatic cancer. FDA approval for RASONQUE in metastatic pancreatic cancer transforms RVMD's competitive standing and long-term outlook.

5 www.fool.com, 7:27 AM
Revolution Medicines received FDA approval one month after filing. Analysts forecast $11.5 billion in peak sales. The stock has risen more than fivefold. FDA approval plus $11.5 billion peak sales projection marks a fundamental redefinition of Revolution Medicines competitive position.

4 , 4:54 PM
Revolution Medicines achieved a historic breakthrough in pancreatic cancer treatment. The company's $47 billion valuation indicates the market had already priced in such success. Pancreatic cancer treatment breakthrough marks major clinical success likely to significantly alter company trajectory and investor sentiment.

4 , 12:18 PM
UBS forecasts a strong launch for Revolution Medicines' Rasonque product. Positive analyst view on Rasonque launch signals major revenue and trajectory gains for Revolution Medicines.

4 , 10:13 AM
Revolution Medicines launches new pancreatic cancer drug at $39,800 monthly list price. RVMD new pancreatic cancer drug launch at premium monthly price signals major commercial entry into oncology market.

4 , 2:18 AM
Revolution Medicines (RVMD) obtained RASONQUE approval, leaving its valuation narrative under scrutiny for sustainability. RASONQUE approval marks a critical regulatory milestone capable of substantially shifting company trajectory and investor views.

27 Aug

5 , 7:12 PM
Revolution Medicines receives first-in-class RASONQUE approval in pancreatic cancer, triggering investor reactions to RVMD stock and outlook. First-in-class pancreatic cancer approval marks transformative regulatory win for RVMD pipeline and market position.

5 , 1:00 PM
Revolution Medicines secures FDA approval for Rasonque in pancreatic cancer. FDA approval for Rasonque in pancreatic cancer transforms RVMD revenue potential and market position.

5 www.thedailyupside.com, 12:01 AM
Revolution Medicines secures early FDA approval for its pancreatic cancer drug, a development positioned to extend patient survival and drive company growth. Early FDA approval of a core pancreatic cancer therapy opens major revenue streams and redefines RVMD market position.

4 , 3:11 PM
Revolution Medicines (RVMD) secures approval with direct implications for metastatic pancreatic cancer treatment options. RVMD approval opens major new oncology market opportunities and shifts competitive positioning.

4 stocktwits.com, 2:54 PM
Revolution Medicines prices its cancer drug at $39,800 monthly, focusing attention on patient access, while CEO Goldsmith expects insurers to provide coverage swiftly. Pricing and swift coverage expectations for RVMD's lead cancer drug signal major revenue potential and market trajectory shift.

4 , 12:21 PM
Oppenheimer states Revolution Medicines' Rasonque label expansion widens commercial opportunity for RVMD. Rasonque label expansion materially lifts RVMD revenue potential and investor outlook.

26 Aug

4 , 6:33 PM
Wall Street views Revolution Medicines' $39,800 pancreatic cancer pill as validation of larger company potential. RVMD pancreatic cancer pill pricing signals major market opportunity and growth trajectory shift.

4 stocktwits.com, 6:22 PM
RVMD secures drug approval, prompting Sellas traders to anticipate competition in pancreatic cancer while Sellas prioritizes its leukemia pipeline near term. RVMD drug approval marks major regulatory success that can significantly shift company trajectory and investor sentiment.

4 stocktwits.com, 3:52 PM
Revolution Medicines receives FDA approval for pancreatic cancer pill at $39,800 monthly, yet stock stays flat with questions if price overshadows the approval. FDA approval constitutes major regulatory milestone and product launch with potential to alter long-term revenue trajectory and market position.

3 , 6:17 PM
Onco360 has been selected as a national pharmacy partner for Revolution Medicines' RASONQUE (daraxonrasib). Pharmacy partnership supports commercial distribution and market access for daraxonrasib.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us